Roivant Sciences Stock News

Roivant Sciences Ltd. - Special Call Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO & Director Benjamin Zimmer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Yaron Werber - TD Cowen, Res...

Shares of Roivant Sciences (ROIV 12.14%) are soaring 11.4% higher as of 11:19 a.m. ET on Wednesday.

Shares of Roivant Sciences extended their breakout Wednesday, stoked by promising test results in a difficult-to-treat autoimmune disease.

Roivant and partner Priovant Therapeutics said on Wednesday that their experimental drug for a rare disease affecting both skin and muscle health has shown promising results in a late-stage clinical trial.

BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis (DM).

BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Great Place To Work® and Fortune magazine have selected Roivant (Nasdaq: ROIV) for the 2025 Fortune Best Workplaces in BioPharma™ List. This is Roivant's first time being named to this prestigious list, coming in at 28th place in the small & medium category. Earning a spot means that Roivant is one of the best compan...

Roivant Sciences Ltd. (NASDAQ:ROIV ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 5:35 PM EDT Company Participants Matthew Gline - CEO & Director Conference Call Participants Albert Wong - Morgan Stanley Presentation Albert Wong Good afternoon, everybody, and thanks for being here powering through towards the end of the day.

Orphan drug designation from Japan's Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments targeting diseases for which there is no sufficient alternative A global Phase 2 PHocus study of mosliciguat in PH-ILD is currently ongoing and will be highlighted in a study-in-progress poster at the Eur...